Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -11.05% is 58% above its 5-year average of -26.23%, near the high end of its 5-year range (-35.63%–-11.05%).
42.88% above its 12-month average of -19.34%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -3.34%.
RETURN ON ASSETS (ROA)
-11.05%
RETURN ON ASSETS (ROA) AVG TTM
-19.34%
RETURN ON ASSETS (ROA) AVG 3Y
-25.88%
RETURN ON ASSETS (ROA) AVG 5Y
-26.23%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+42.88%
CURRENT VS 3Y AVG
+57.31%
CURRENT VS 5Y AVG
+57.88%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.11%
median of 628 covered companies
CURRENT VS SECTOR MEDIAN
+62.04%
vs the sector median at left
Establishment Labs Holdings Inc.
Market Cap
$1.95B
Return on Assets (ROA)
-11.05%
TTM Avg
-19.34%
3Y Avg
-25.88%
5Y Avg
-26.23%
Market Cap
$1.96B
Return on Assets (ROA)
-11.00%
TTM Avg
-5.98%
3Y Avg
-9.46%
5Y Avg
-10.43%
Market Cap
$1.93B
Return on Assets (ROA)
-44.98%
TTM Avg
-76.52%
3Y Avg
-94.59%
5Y Avg
-76.85%
Market Cap
$2.00B
Return on Assets (ROA)
14.58%
TTM Avg
11.33%
3Y Avg
2.89%
5Y Avg
-3.84%
Market Cap
$2.00B
Return on Assets (ROA)
-52.34%
TTM Avg
-54.87%
3Y Avg
-41.09%
5Y Avg
-94.89%
Market Cap
$2.00B
Return on Assets (ROA)
39.65%
TTM Avg
19.63%
3Y Avg
0.51%
5Y Avg
-8.90%
Market Cap
$2.01B
Return on Assets (ROA)
-68.96%
TTM Avg
16.60%
3Y Avg
-13.89%
5Y Avg
-23.58%
Market Cap
$1.89B
Return on Assets (ROA)
-6.55%
TTM Avg
-5.28%
3Y Avg
-5.65%
5Y Avg
-2.06%
Market Cap
$1.89B
Return on Assets (ROA)
11.27%
TTM Avg
-4.02%
3Y Avg
-13.89%
5Y Avg
-9.34%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.95B | -11.05% | -19.34% | -25.88% | -26.23% |
| AxoGen, Inc. (AXGN)vs › | $1.96B | -11.00% | -5.98% | -9.46% | -10.43% |
| Immunome, Inc. (IMNM)vs › | $1.93B | -44.98% | -76.52% | -94.59% | -76.85% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.00B | 14.58% | 11.33% | 2.89% | -3.84% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.00B | -52.34% | -54.87% | -41.09% | -94.89% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.00B | 39.65% | 19.63% | 0.51% | -8.90% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.01B | -68.96% | 16.60% | -13.89% | -23.58% |
| Azenta, Inc. (AZTA)vs › | $1.89B | -6.55% | -5.28% | -5.65% | -2.06% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 11.27% | -4.02% | -13.89% | -9.34% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.87B | -37.11% | 4.34% | -11.90% | 4.27% |
ROA
-11.1%
ROE
-180.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -14.30% |
| 2024-12-31 | -24.39% |
| 2023-12-31 | -29.22% |
| 2022-12-31 | -35.63% |
| 2021-12-31 | -29.48% |
| 2020-12-31 | -24.38% |
| 2019-12-31 | -32.74% |
| 2018-12-31 | -18.10% |
| 2017-12-31 | -61.12% |
| 2016-12-31 | -74.96% |
